[{"id":"b7618037-1369-4803-9a4d-36cc465a98d2","acronym":"","url":"https://clinicaltrials.gov/study/NCT07159906","created_at":"2025-09-13T08:44:39.729Z","updated_at":"2025-09-13T08:44:39.729Z","phase":"Phase 1/2","brief_title":"Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT07159906","lead_sponsor":"First Affiliated Hospital of Zhejiang University","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • prednisone • lisaftoclax (APG-2575) • Synribo (omacetaxine mepesuccinate)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 09/08/2025","start_date":" 09/08/2025","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 08/01/2028","study_completion_date":" 08/01/2028","last_update_posted":"2025-09-08"},{"id":"16167a12-edc3-4776-9942-2975c9714e30","acronym":"","url":"https://clinicaltrials.gov/study/NCT03258593","created_at":"2025-06-07T14:49:21.304Z","updated_at":"2025-06-07T14:49:21.304Z","phase":"Phase 1","brief_title":"Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)","source_id_and_acronym":"NCT03258593","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Vicineum (oportuzumab monatox)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 06/07/2018","start_date":" 06/07/2018","primary_txt":" Primary completion: 08/01/2022","primary_completion_date":" 08/01/2022","study_txt":" Completion: 10/17/2022","study_completion_date":" 10/17/2022","last_update_posted":"2025-05-30"},{"id":"7a2918a3-5cca-4af4-9ede-643ba7496c81","acronym":"","url":"https://clinicaltrials.gov/study/NCT01745588","created_at":"2021-01-18T07:39:01.782Z","updated_at":"2025-02-25T14:33:53.694Z","phase":"Phase 2","brief_title":"Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma","source_id_and_acronym":"NCT01745588","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pomalidomide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 12/01/2012","start_date":" 12/01/2012","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-07-03"},{"id":"893adf5f-401b-45ed-b55a-95592085576f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04874194","created_at":"2021-05-05T11:52:46.095Z","updated_at":"2024-07-02T16:35:02.356Z","phase":"Phase 1/2","brief_title":"Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1","source_id_and_acronym":"NCT04874194","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" RUNX1","pipe":" | ","alterations":" RUNX1 mutation","tags":["RUNX1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RUNX1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Synribo (omacetaxine mepesuccinate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 12/17/2021","start_date":" 12/17/2021","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2024-05-21"},{"id":"a40edb33-4956-4fcb-af35-db7081c0b606","acronym":"","url":"https://clinicaltrials.gov/study/NCT06328179","created_at":"2024-03-25T17:36:14.935Z","updated_at":"2024-07-02T16:35:12.972Z","phase":"","brief_title":"Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.","source_id_and_acronym":"NCT06328179","lead_sponsor":"Huai'an First People's Hospital","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • etoposide IV • Synribo (omacetaxine mepesuccinate)"],"overall_status":"Recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 05/24/2022","start_date":" 05/24/2022","primary_txt":" Primary completion: 12/30/2027","primary_completion_date":" 12/30/2027","study_txt":" Completion: 12/30/2027","study_completion_date":" 12/30/2027","last_update_posted":"2024-03-25"},{"id":"f576a83a-4927-4ebe-9a09-b7fb566e9364","acronym":"","url":"https://clinicaltrials.gov/study/NCT05495854","created_at":"2022-08-10T12:55:35.521Z","updated_at":"2024-07-02T16:35:36.928Z","phase":"","brief_title":"New Strategy for the Detection and Treatment of Helicobacter Pylori Infections in Primary Care Guided by a Non-invasive PCR in Stool","source_id_and_acronym":"NCT05495854","lead_sponsor":"Poitiers University Hospital","biomarkers":" MSH2","pipe":"","alterations":" ","tags":["MSH2"],"overall_status":"Recruiting","enrollment":" Enrollment 1100","initiation":"Initiation: 02/03/2023","start_date":" 02/03/2023","primary_txt":" Primary completion: 02/03/2024","primary_completion_date":" 02/03/2024","study_txt":" Completion: 02/03/2024","study_completion_date":" 02/03/2024","last_update_posted":"2023-09-14"},{"id":"3dc09b40-82a5-425d-b8e9-5b1b7d8b100e","acronym":"","url":"https://clinicaltrials.gov/study/NCT00462943","created_at":"2021-12-28T22:53:39.815Z","updated_at":"2024-07-02T16:36:19.138Z","phase":"Phase 2","brief_title":"Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML","source_id_and_acronym":"NCT00462943","lead_sponsor":"Teva Branded Pharmaceutical Products R\u0026D, Inc.","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Synribo (omacetaxine mepesuccinate)"],"overall_status":"Completed","enrollment":" Enrollment 100","initiation":"Initiation: 03/07/2007","start_date":" 03/07/2007","primary_txt":" Primary completion: 08/04/2009","primary_completion_date":" 08/04/2009","study_txt":" Completion: 06/27/2013","study_completion_date":" 06/27/2013","last_update_posted":"2021-12-28"},{"id":"e42a85e3-8a8f-4ba5-b42b-6faaef554669","acronym":"","url":"https://clinicaltrials.gov/study/NCT00375219","created_at":"2021-11-11T18:45:16.493Z","updated_at":"2024-07-02T16:36:20.742Z","phase":"Phase 2","brief_title":"Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation","source_id_and_acronym":"NCT00375219","lead_sponsor":"Teva Branded Pharmaceutical Products R\u0026D, Inc.","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Synribo (omacetaxine mepesuccinate)"],"overall_status":"Completed","enrollment":" Enrollment 103","initiation":"Initiation: 09/20/2006","start_date":" 09/20/2006","primary_txt":" Primary completion: 03/23/2010","primary_completion_date":" 03/23/2010","study_txt":" Completion: 06/28/2013","study_completion_date":" 06/28/2013","last_update_posted":"2021-11-15"},{"id":"b6c77732-afc6-4da0-815e-7108b1d9bd90","acronym":"","url":"https://clinicaltrials.gov/study/NCT00450944","created_at":"2021-01-18T01:35:50.105Z","updated_at":"2024-07-02T16:36:31.946Z","phase":"Phase 1","brief_title":"Anti-CD19 and Anti-CD22 Immunotoxins in Treating Patients With Refractory or Relapsed B-Cell Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT00450944","lead_sponsor":"Albert Einstein College of Medicine","biomarkers":" CD19 • CD22","pipe":" | ","alterations":" CD19 expression","tags":["CD19 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Combotox (Imtox19/Imtox22)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 02/22/2006","start_date":" 02/22/2006","primary_txt":" Primary completion: 10/27/2008","primary_completion_date":" 10/27/2008","study_txt":" Completion: 04/01/2010","study_completion_date":" 04/01/2010","last_update_posted":"2021-04-14"},{"id":"bf75e380-cf06-45ab-9526-c6dc47a6700e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04505995","created_at":"2021-01-18T21:36:19.252Z","updated_at":"2024-07-02T16:36:42.207Z","phase":"","brief_title":"Azacitidine and Homoharringtonine in JMML","source_id_and_acronym":"NCT04505995","lead_sponsor":"Fourth Military Medical University","biomarkers":" KRAS • NRAS • PTPN11","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • PTPN11 mutation","tags":["KRAS • NRAS • PTPN11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • PTPN11 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • Synribo (omacetaxine mepesuccinate)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/01/2020","start_date":" 01/01/2020","primary_txt":" Primary completion: 01/01/2023","primary_completion_date":" 01/01/2023","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2020-08-10"},{"id":"a5412ef0-8de3-48a3-beec-bb96a1550b73","acronym":"MOXE","url":"https://clinicaltrials.gov/study/NCT03501615","created_at":"2021-01-18T17:13:55.556Z","updated_at":"2024-07-02T16:36:43.783Z","phase":"","brief_title":"An Early Access Programme for Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia","source_id_and_acronym":"NCT03501615 - MOXE","lead_sponsor":"AstraZeneca","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lumoxiti (moxetumomab pasudotox)"],"overall_status":"Approved for marketing","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2020-06-29"},{"id":"2f7a5d93-470c-4333-bbd7-fc38933e1084","acronym":"PLAIT","url":"https://clinicaltrials.gov/study/NCT01829711","created_at":"2021-01-18T08:08:03.726Z","updated_at":"2024-07-02T16:36:46.386Z","phase":"Phase 3","brief_title":"Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia","source_id_and_acronym":"NCT01829711 - PLAIT","lead_sponsor":"MedImmune LLC","biomarkers":" BRAF • CD22","pipe":"","alterations":" ","tags":["BRAF • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lumoxiti (moxetumomab pasudotox)"],"overall_status":"Completed","enrollment":" Enrollment 80","initiation":"Initiation: 04/29/2013","start_date":" 04/29/2013","primary_txt":" Primary completion: 05/24/2017","primary_completion_date":" 05/24/2017","study_txt":" Completion: 04/29/2019","study_completion_date":" 04/29/2019","last_update_posted":"2020-04-08"},{"id":"f1b173cf-5e6a-4243-a2dc-cddb4fa79a72","acronym":"","url":"https://clinicaltrials.gov/study/NCT02370160","created_at":"2021-01-18T11:17:26.599Z","updated_at":"2024-07-02T16:36:51.390Z","phase":"Phase 1/2","brief_title":"HM2014-26 DT2219 for Relapsed or Refractory B-Lineage Leukemia or Lymphoma","source_id_and_acronym":"NCT02370160","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" CD22","pipe":"","alterations":" ","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e OXS-1550"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 12/21/2015","start_date":" 12/21/2015","primary_txt":" Primary completion: 04/08/2018","primary_completion_date":" 04/08/2018","study_txt":" Completion: 04/08/2018","study_completion_date":" 04/08/2018","last_update_posted":"2020-01-13"},{"id":"bd046914-1a8f-4bf4-839a-b7db634f7c51","acronym":"","url":"https://clinicaltrials.gov/study/NCT00586924","created_at":"2021-01-18T02:09:41.853Z","updated_at":"2024-07-02T16:37:01.009Z","phase":"Phase 1","brief_title":"A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia","source_id_and_acronym":"NCT00586924","lead_sponsor":"MedImmune LLC","biomarkers":" CD22","pipe":" | ","alterations":" CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lumoxiti (moxetumomab pasudotox)"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 05/10/2007","start_date":" 05/10/2007","primary_txt":" Primary completion: 05/06/2015","primary_completion_date":" 05/06/2015","study_txt":" Completion: 05/06/2015","study_completion_date":" 05/06/2015","last_update_posted":"2019-04-02"},{"id":"1a1dde8f-4cf8-4ee4-a9e7-22cc3ac6da9b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01030536","created_at":"2021-01-18T04:02:44.352Z","updated_at":"2024-07-02T16:37:11.654Z","phase":"Phase 1/2","brief_title":"Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL)","source_id_and_acronym":"NCT01030536","lead_sponsor":"MedImmune LLC","biomarkers":" CD22","pipe":" | ","alterations":" CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lumoxiti (moxetumomab pasudotox)"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 02/15/2010","start_date":" 02/15/2010","primary_txt":" Primary completion: 03/04/2013","primary_completion_date":" 03/04/2013","study_txt":" Completion: 03/04/2013","study_completion_date":" 03/04/2013","last_update_posted":"2018-04-09"},{"id":"5e8b88b8-ff47-433a-a99e-7a4b183ba806","acronym":"","url":"https://clinicaltrials.gov/study/NCT00889408","created_at":"2021-01-18T03:24:18.974Z","updated_at":"2024-07-02T16:37:15.928Z","phase":"Phase 1","brief_title":"DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma","source_id_and_acronym":"NCT00889408","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" CD22","pipe":"","alterations":" ","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e OXS-1550"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 12/02/2013","start_date":" 12/02/2013","primary_txt":" Primary completion: 07/21/2014","primary_completion_date":" 07/21/2014","study_txt":" Completion: 07/21/2014","study_completion_date":" 07/21/2014","last_update_posted":"2017-12-02"},{"id":"9aa724b6-3ee9-4fe7-873d-6366f5237f5e","acronym":"","url":"https://clinicaltrials.gov/study/NCT00659425","created_at":"2021-01-18T02:27:28.183Z","updated_at":"2024-07-02T16:37:17.400Z","phase":"Phase 1","brief_title":"CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT00659425","lead_sponsor":"MedImmune LLC","biomarkers":" CD22","pipe":" | ","alterations":" CD22 positive • CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 positive • CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lumoxiti (moxetumomab pasudotox)"],"overall_status":"Completed","enrollment":" Enrollment 57","initiation":"Initiation: 09/01/2008","start_date":" 09/01/2008","primary_txt":" Primary completion: 12/01/2014","primary_completion_date":" 12/01/2014","study_txt":" Completion: 12/01/2014","study_completion_date":" 12/01/2014","last_update_posted":"2017-10-02"},{"id":"16b0da6f-245d-47b0-a45e-00b6509e57da","acronym":"","url":"https://clinicaltrials.gov/study/NCT00460109","created_at":"2021-01-18T01:38:02.217Z","updated_at":"2024-07-02T16:37:23.304Z","phase":"Phase 2","brief_title":"Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT00460109","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" ALB","pipe":"","alterations":" ","tags":["ALB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Ontak (denileukin diftitox)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 04/01/2008","start_date":" 04/01/2008","primary_txt":" Primary completion: 10/01/2010","primary_completion_date":" 10/01/2010","study_txt":" Completion: 03/01/2011","study_completion_date":" 03/01/2011","last_update_posted":"2017-04-18"}]